Research & Development

Infant Bacterial Therapeutics' most advanced clinical program is the IBP-9414 project developing a preventive treatment against necrotizing enterocolitis (NEC).   The phase II safety and tolerability study in premature infants started in 2016 The active bacteri...
Read More

What we do

Infant Bacterial Therapeutics AB (publ) (“IBT”) is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therape...
Read More